Paper40114780
Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.
Pathak V and 2 others. Kona, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections. Papers, record 40114780. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40114780
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI146160 | NIAID NIH HHS | United States | R01AI146160 | PubMed and NIH | NIH RePORTER |
| R01 HL167828 | NHLBI NIH HHS | United States | R01HL167828 | PubMed and NIH | NIH RePORTER |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33202354 | Unlocking the next generation of phage therapy: the key is in the receptors. | Curr Opin Biotechnol | 2021 | https://conductscience.org/library/papers/33202354 | PubMed |
| 2 | 26442188 | Phage therapy of pulmonary infections. | Bacteriophage | 2015 | https://conductscience.org/library/papers/26442188 | PubMed |
| 3 | 23360765 | Unraveling protein stabilization mechanisms: vitrification and water replacement in a glass transition temperature controlled system. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/23360765 | PubMed |
| 4 | 30763536 | Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. | Cell Host Microbe | 2019 | https://conductscience.org/library/papers/30763536 | PubMed |
| 5 | 25254623 | Update on the antibiotic resistance crisis. | Curr Opin Pharmacol | 2014 | https://conductscience.org/library/papers/25254623 | PubMed |
| 6 | 34452123 | The Influence of Formulation Components and Environmental Humidity on Spray-Dried Phage Powders for Treatment of Respiratory Infections Caused by Acinetobacter baumannii. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34452123 | PubMed |
| 7 | 11823954 | Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Clin Infect Dis | 2002 | https://conductscience.org/library/papers/11823954 | PubMed |
| 8 | 24950368 | Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. | Int J Pharm | 2014 | https://conductscience.org/library/papers/24950368 | PubMed |
| 9 | 36140035 | Activity of Phage-Lactoferrin Mixture against Multi Drug Resistant Staphylococcus aureus Biofilms. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/36140035 | PubMed |
| 10 | 12846264 | The threat from the pink corner. | Ann Med | 2003 | https://conductscience.org/library/papers/12846264 | PubMed |
| 11 | 32440564 | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization. | Bioeng Transl Med | 2020 | https://conductscience.org/library/papers/32440564 | PubMed |
| 12 | 31845128 | Trileucine and Pullulan Improve Anti-Campylobacter Bacteriophage Stability in Engineered Spray-Dried Microparticles. | Ann Biomed Eng | 2020 | https://conductscience.org/library/papers/31845128 | PubMed |
| 13 | 33302377 | Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens. | Molecules | 2020 | https://conductscience.org/library/papers/33302377 | PubMed |
| 14 | 38247630 | New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/38247630 | PubMed |
| 15 | 20196657 | Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. | J Infect Dis | 2010 | https://conductscience.org/library/papers/20196657 | PubMed |
| 16 | 27776446 | Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections. | Expert Opin Drug Deliv | 2017 | https://conductscience.org/library/papers/27776446 | PubMed |
| 17 | 22334867 | Pros and cons of phage therapy. | Bacteriophage | 2011 | https://conductscience.org/library/papers/22334867 | PubMed |
| 18 | 29777836 | Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. | Res Microbiol | 2018 | https://conductscience.org/library/papers/29777836 | PubMed |
| 19 | 27130366 | Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying. | Int J Pharm | 2016 | https://conductscience.org/library/papers/27130366 | PubMed |
| 20 | 38081559 | Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation. | Int J Pharm | 2024 | https://conductscience.org/library/papers/38081559 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42495612 | Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42495612 | PubMed |
| 40871096 | Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871096 | PubMed |
| 40760229 | Long-term Storage Stability of Inhalable Phage Powder Formulations: A Four-Year Study. | AAPS J | 2025 | https://conductscience.org/library/papers/40760229 | PubMed |
| 40426553 | Virological and Pharmaceutical Properties of Clinically Relevant Phages. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40426553 | PubMed |
| 40250500 | Powder aerosol formulation of Pseudomonas aeruginosa bacteriophage for pulmonary delivery. | Int J Pharm | 2025 | https://conductscience.org/library/papers/40250500 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40114780
GET https://conductscience.org/api/papers/v1/40114780/references?page=2